• Four existing pipeline programs address underlying genetic causes
• Proceeds will fund clinical development into 2030
• Deliver key clinical data across all four pipeline programs

PYC Therapeutics, a company developing precision RNA therapies for genetic diseases, is raising up to approximately A$653 million through an equity issuance consisting of an A$128 million institutional placement and a 3 for 5 pro-rata accelerated non-renounceable entitlement offer to add approximately A$525 million. The placement will enable specialist life sciences investors to join the company's share register, while the rights issue will allow existing shareholders to participate on the same terms. Successful completion of the offering will provide PYC with a cash runway extending into 2030, enabling the company to deliver important clinical efficacy data across all four of its pipeline programs. This includes read-outs on the registrational endpoints in its Polycystic Kidney Disease program, human safety and early efficacy data in its Phelan-McDermid Syndrome program, and ongoing phase 1/2 studies in the company's two blinding eye disease programs to support progression of these drug candidates into registrational trials. The capital raise will also create optionality in the commercialization pathway by advancing all four drug development programs into the transactional window and building a shareholder register capable of supporting the company's transition to a commercial-stage company.

Successful completion of the Offer will provide the Company with a cash runway extending into CY2030, enabling PYC to deliver important clinical efficacy data across all four of its pipeline programs.